Results 101 to 110 of about 31,215 (290)

Use of Glucagon‐Like Peptide‐1 Receptor Agonists and Risk of Parkinson's Disease: Scandinavian Cohort Study

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To investigate the association between use of GLP‐1 receptor agonists and incident Parkinson's disease. Material and Methods Cohort study using data from nationwide registers in Denmark, Norway and Sweden and an active‐comparator, new‐user design.
Arvid Engström, Henrik Svanström, Anders Hviid, Björn Eliasson, Soffia Gudbjörnsdottir, Viktor Wintzell, Kristian Hveem, Christian Jonasson, Mads Melbye, Peter Ueda, Björn Pasternak   +10 more
wiley   +1 more source

Discontinuation of SGLT2i After a Urogenital Infection: A Population‐Based Matched Cohort Study of Patients With Type 2 Diabetes

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Sodium‐glucose cotransporter 2 inhibitors (SGLT2is) improve glycaemic control and cardiorenal outcomes in Type 2 diabetes, particularly in patients at elevated cardiovascular and kidney risk, yet discontinuation following infections appears common.
Christine Ljungberg, Mette Nørgaard, Christina Vandenbroucke‐Grauls, Michael Dalager‐Pedersen, Henrik Toft Sørensen, Reimar Wernich Thomsen   +5 more
wiley   +1 more source

Sulfonylureas.

JPMA. The Journal of the Pakistan Medical Association, 2015
This review describes the basic and clinical pharmacology of sulfonylureas. It undertakes a balanced assessment of the advantages and limitations of sulfonylureas, and compares the use of various sulfonylureas in different clinical situations. The authors suggest pragmatic guidance to facilitate safe and effective use of this class of drugs, and thus ...
Sanjay, Kalra, Yashdeep, Gupta
openaire   +1 more source

Sitagliptin, Metformin and Glimepiride Fixed‐Dose Combination Compared to Co‐Administration of Metformin and High‐Dose Glimepiride in Indian Patients With Type 2 Diabetes: A Randomised, Double‐Blind, Double‐Dummy, Phase 3 Clinical Study

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims This study assessed the efficacy and safety of a triple fixed‐dose combination (FDC) of sitagliptin, metformin, and glimepiride versus co‐administered metformin and glimepiride in Indian patients with uncontrolled Type 2 diabetes (T2D).
Rakesh Sahay, Ambanna Gowda, Manish Kumar Singh, A. Gopal Rao, Ramesh Duraisamy, Dinesh Gangwani, Jitendra Shukla, Vikas Agarwal, Sandesh Sahebarao Patil, Ambrish C., Satish Babu K. N., Arvind Palawat, Sandip Krishnrao Gofne, Abhay Kumar Sahoo, Pradeep Kumar Rai, Raisa Shaikh, Shruti Saha, Dipak Patil, Pravin Ghadge, Piyush Patel, Lalit Lakhwani, Suyog Mehta, Sadhna Joglekar   +22 more
wiley   +1 more source

Pharmacogenomics in diabetes mellitus:insights into drug action and drug discovery [PDF]

, 2016
Genomic studies have greatly advanced our understanding of the multifactorial aetiology of type 2 diabetes mellitus (T2DM) as well as the multiple subtypes of monogenic diabetes mellitus.
A American Diabetes, A Bossi, A Dornhorst, A Mullard, AA Tahrani, Adem Y. Dawed, AJ Mulherin, AK Daly, AK Daly, AL Gloyn, AM Simonis-Bik, AP Gjesing, AP Morris, AR Harper, AV Segre, C Cao, C Global Lipids Genetics, C Mizzi, CE Elks, CF Deacon, CJ Bailey, CJ Bailey, CJ Bailey, CS Greene, DB Goldstein, DB Goldstein, DF Carr, E Pearson, EA Stein, EJ Verspohl, ER Pearson, ER Pearson, ES Kang, Ewan R. Pearson, FM Gribble, FS Collins, GG Graham, H Carter, H Schunkert, H Yki-Jarvinen, H Zhang, Helle Krogh Pedersen, I Watanabe, IM Stratton, J Flannick, J Taneera, J Yang, J Yang, J Yang, JC Cohen, JC Cohen, JN Todd, JT Erler, K Forslund, K Suzuki, K Zhou, K Zhou, K Zhou, K Zhou, K Zhou, K Zhou, KA Jablonski, Kaixin Zhou, KJ Gaulton, KL Mohlke, L Rossetti, L Tarasova, L Van Gaal, LJ McCreight, LM t Hart, M Abifadel, M Hay, M Javorsky, M Javorsky, M Stumvoll, M Tamaki, M Zhang, MC Hsieh, MK Hellerstein, ML Becker, ML Becker, ML Becker, MR Nelson, MR Nelson, N Siva, N van Leeuwen, NM De Silva, O Gokalp, O Magger, P Csermely, PJ Connelly, PM Visscher, PM Visscher, Q Pei, R Kumashiro, R Sabino-Silva, R Santer, RA Miller, RB Prasad, RL Chang, RM Plenge, RR Holman, RW Koivula, S Mallal, S Semiz, SD Bailey, T Dujic, T Dujic, T Ideker, TJ Nicolson, V Lyssenko, V Steinthorsdottir, Y Feng, Y Shu, Y Shu, Y Zhang, Y Zhou, Z Schroner   +117 more
core   +3 more sources

Associations of Semaglutide With Skeletal Outcomes in People With Obesity, With and Without Type 2 Diabetes: A Target Trial Emulation

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To evaluate the associations between semaglutide initiation and long‐term skeletal outcomes in people with obesity, stratified by type 2 diabetes (T2D) status, using target trial emulation. Materials and Methods This retrospective cohort study used the TriNetX federated electronic health record network.
Yu‐Nan Huang, Min‐Yu Tsou, Pin‐Hung Li, Jo‐Ching Chen, Shao‐Chia Chen, Hao‐I Hsieh, Gideon Meyerowitz‐Katz, Yen‐Liang Liu, Pen‐Hua Su   +8 more
wiley   +1 more source

Diabetic foot ulcer‐related amputation is associated with twofold increased risk of cardiovascular disease: A Korean National Health Information Database Study

Journal of Diabetes Investigation, EarlyView.
Data/Design: Nationwide, population‐based longitudinal cohort using the Korean National Health Insurance Service health checkup database (index 2009–2012) with follow‐up through December 31, 2018. Population/Exposure: Adults with diabetes (N = 1,229,689); DFU‐related amputation at baseline (n = 1,486) vs no DFU‐related amputation.
Jinsun Jang, Bong‐Seong Kim, Hye Won Yang, Heejun Son, Dong Yeon Lee, Min Gyu Kyung, Hwan Jun Jae, Saebeom Hur, Sang Wha Kim, Sanghyun Ahn, Kyung‐Do Han, Soo Heon Kwak   +11 more
wiley   +1 more source

ChREBP drives β‐cell proliferation under metabolic stress but not in pregnancy‐induced β‐cell expansion

Journal of Diabetes Investigation, EarlyView.
ChREBP is a context‐dependent regulator of adaptive β‐cell proliferation. It plays a pivotal role in driving β‐cell expansion under pathophysiological metabolic stress, such as insulin resistance and hyperglycemia, but has a limited role during physiological expansion in pregnancy.
Sodai Kubota, Seiya Banno, Katsumi Iizuka, Hiromi Tsuchida, Saki Kubota‐Okamoto, Teruaki Sakurai, Yoshihiro Takahashi, Toshinori Imaizumi, Takehiro Kato, Yukio Horikawa, Shin Tsunekawa, Ryota Usui, Hisato Tatsuoka, Shinsuke Tokumoto, Takaaki Murakami, Yuuka Fujiwara, Hitoshi Kuwata, Yuji Yamazaki, Yuichiro Yamada, Yutaka Seino, Daisuke Yabe   +20 more
wiley   +1 more source

Five‐year follow‐up of incretin‐based therapy in a patient with KCNJ11‐related permanent neonatal diabetes: Achieving insulin discontinuation and sulfonylurea reduction

Journal of Diabetes Investigation, EarlyView.
In a woman with KCNJ11‐related permanent neonatal diabetes mellitus, incretin‐based therapy enabled insulin discontinuation and maintained glycemic control for more than 5 years, with HbA1c between 6.1% and 6.5% on the lowest semaglutide dose, dose‐dependent improvement in insulin secretion, and an approximately 60% reduction in glibenclamide dose ...
Toshiaki Ohkuma, Ryoichiro Aotani, Wakako Sakamoto, Ayaka Oshiro, Tetsuro Ago   +4 more
wiley   +1 more source

Deciding oral drugs after metformin in type 2 diabetes: An evidence-based approach

Indian Journal of Endocrinology and Metabolism, 2014
The most commonly used oral drug in treating type 2 diabetes (T2DM) after metformin are sufonylureas (SUs) based on the confidence gained over the several decades and because of its cheaper cost.
Awadhesh Kumar Singh
doaj   +1 more source